Closing the door on flaviviruses: Entry as a target for antiviral drug design
- 11 June 2008
- journal article
- review article
- Published by Elsevier in Antiviral Research
- Vol. 80 (1) , 11-22
- https://doi.org/10.1016/j.antiviral.2008.05.004
Abstract
No abstract availableKeywords
This publication has 167 references indexed in Scilit:
- Pathogenic flavivirusesThe Lancet, 2008
- A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical TrialThe Journal of Infectious Diseases, 2007
- The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus InfectionPublished by Elsevier ,2007
- Solution structure of the envelope protein domain III of dengue-4 virusVirology, 2007
- West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibodyProceedings of the National Academy of Sciences, 2006
- NMR solution structure and backbone dynamics of domain III of the E protein of tick‐borne Langat flavivirus suggests a potential site for molecular recognitionProtein Science, 2006
- A live, attenuated recombinant West Nile virus vaccineProceedings of the National Academy of Sciences, 2006
- A structural perspective of the flavivirus life cycleNature Reviews Microbiology, 2005
- DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic CellsThe Journal of Experimental Medicine, 2003
- The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolutionNature, 1995